Newcastle Laboratories

Dr. Yvonne A. Bury

Yvonne Burry-M

Cellular Pathology

Consultant Histopathologist/Cellular Pathology

Consultant Histopathologist/Cellular Pathology

and Honorary Associate Clinical Lecturer/Newcastle University

State Exam Med (Germany), MD (Germany), FRCPath (UK)

Yvonne trained in Cologne University Hospital and the Northern Rotation including Royal Victoria Infirmary in Newcastle, Durham and James Cook University Hospitals; and Sunderland Royal Hospital.  She has previoulsy obtained an MD from Heinrich-Heine-University Duesseldorf following her medical state exam.

She was appointed Consultant Histopathologist in Newcastle in 2012 after completion of her Academic Clinical Fellowship with Newcastle University.  Her special expertise includes liver/HPB/GI and breast pathology.

She has a keen research interest in hepatopancreaticobiliary diseases including PBC, fatty liver disease and hepatocellular carcinoma; as well as breast and colorectal carcinoma.

 

Publications:

  • Gill MD, Bramble MG, Hull MA, Mills SJ, Morris E, Bradburn DM, Bury Y, Parker CE, Lee TJ, Rees CJ. Screen-detected colorectal cancers are associated with an improved outcome compared with stage-matched interval cancers. British Journal of Cancer 2014, 111, 2076-2081.
  • Bedossa P, Burt AD, Gouw AS, Lackner C, Schirmacher P, Terracciano L, Tiniakos D, Brain J, Bury Y, Cabibi D, Charlotte F, David E, Losi L, Montani M, Pareja MJ, Wendum D, Wrba F, Ziol M, Ratziu V. Utility and appropriateness of the FLIP algorithm and SAF score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatology 2014, 60(2), 565-575.
  • Sampson J, Bury Y. The enhanced role of biomedical scientists in the histological dissection of axillary lymph node clearance specimens. In: 26th European Congress of Pathology (ECP 2014). 2014, Excel centre, London.
  • Bury Y, Brown N, Karanikolas M, Palaiologou M, Fatourou E, Karandrea D, Antoniou E, Felekouras E, Koskinas J, Delladetsima J, Tiniakos D. p53 expression in human hepatocellular carcinoma (HCC): correlation with dysadherin expression and patient prognosis. In: BASL Annual Meeting 2014. 2014.
  • Orr J, Bury Y, Hudson M, Masson S. Liver transplantation for acute liver failure caused by macrophage activation syndrome. Transplant International 2013, 26(11), e105-e108.
  • Gill MD, Bramble M, Hull M, Mills S, Morris E, Bradburn M, Bury Y, Parker C, Lee T, Rees C. SCREEN-DETECTED COLORECTAL CANCERS ARE ASSOCIATED WITH AN IMPROVED OUTCOME WHEN COMPARED WITH INTERVAL CANCERS WHEN MATCHED FOR STAGE. In: GUT. 2013, BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND: BMJ PUBLISHING GROUP.
  • Kirkham N, Bury Y, Thampy N, Upadhye S. A Structured Approach to the Diagnosis of Borderline Melanocytic Skin Lesions. In: JOURNAL OF PATHOLOGY. 2013, 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.
  • Bury Y, Green R, Jain M, Moor J. Metastasis of carcinoma of the lung to a carotid body paraganglioma. BMJ Case Rep 2012.
  • Bury YA, Chalhoub T, Ralte AM. Gamna-Gandy Bodies Associated with Corpora Albicantia. In: JOURNAL OF PATHOLOGY. 2011, COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA: WILEY-BLACKWELL.
  • Svec A, Bury Y. Haemangioma of the parathyroid gland. Does it really exist?. Pathology & Oncology Research 2010, 16(3), 443-446.
  • Svec A, Wilkinson L, Bury Y, Martin VG. A new piece in the melanoma mosaic–carcinosarcoma-like melanoma. Histopathology 2009, Sep;55(3), 366-8.
  • Odenthal M, Koenig S, Farbrother P, Drebber U, Bury Y, Dienes HP, Eichinger L. Detection of opportunistic infections by low-density microarrays: a diagnostic approach for granulomatous lymphadenitis. Diagn Mol Pathol 2007, Mar;16(1), 18-26.
  • Bury Y. In Vitro Evaluation of Vitamin D Analogues. BOD, 2004.
  • Carlberg C, Quack M, Herdick M, Bury Y, Polly P, Toell A. Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues. Steroids 2001, Mar-May;66(3-5), 213-21.
  • Bury Y, Herdick M, Uskokovic MR, Carlberg C. Gene regulatory potential of 1alpha,25-dihydroxyvitamin D(3) analogues with two side chains. J Cell Biochem 2001, Suppl. 2001;Suppl 36, 179-90.
  • Bury Y, Ruf D, Hansen CM, Kissmeyer AM, Binderup L, Carlberg C. Molecular evaluation of vitamin D3 receptor agonists designed for topical treatment of skin diseases. J Invest Dermatol 2001, May;116(5), 785-92.
  • Herdick M, Bury Y, Quack M, Uskokovic MR, Polly P, Carlberg C. Response element and coactivator-mediated conformational change of the vitamin D(3) receptor permits sensitive interaction with agonists. Mol Pharmacol 2000, 57(6), 1206-17.
  • Bury Y, Steinmeyer A, Carlberg C. Structure activity relationship of carboxylic ester antagonists of the vitamin D(3) receptor. Mol Pharmacol 2000, Nov;58(5), 1067-74.